In-stent restenosis in the drug-eluting stent era

Journal of the American College of Cardiology

Volumn 56, Issue 23, 2010, Pages 1897-1907

  Dangas, George D ^a,b   Claessen, Bimmer E ^b   Caixeta, Adriano ^b   Sanidas, Elias A ^b   Mintz, Gary S ^b   Mehran, Roxana ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Drug eluting stent(s); In stent restenosis; Target lesion revascularization

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; BAROTRAUMA; BRACHYTHERAPY; CORONARY ARTERY BYPASS GRAFT; DRUG DISTRIBUTION; DRUG ELUTING STENT; DRUG RESISTANCE; HEART INFARCTION; HUMAN; HYPERSENSITIVITY; IN-STENT RESTENOSIS; INCIDENCE; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; BRACHYTHERAPY; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; INCIDENCE; MYOCARDIAL REVASCULARIZATION; PROSTHESIS FAILURE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 78649365632     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.07.028     Document Type: Review

References (83)

1. G. Dangas, and V. Fuster Management of restenosis after coronary intervention Am Heart J 132 1996 428 436
2. C. Stettler, S. Wandel, and S. Allemann Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 2007 937 948
3. R. Mehran, G. Dangas, and A.S. Abizaid Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome Circulation 100 1999 1872 1878
4. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
5. A.S. Abizaid, G.S. Mintz, and R. Mehran Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions Circulation 100 1999 256 261
6. V. Jasti, E. Ivan, V. Yalamanchili, N. Wongpraparut, and M.A. Leesar Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis Circulation 110 2004 2831 2836 (Pubitemid 39473605)
7. H. Doi, A. Maehara, and G.S. Mintz Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization- free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials Circ Cardiovasc Interv 1 2008 111 118
8. G.W. Stone, S.G. Ellis, and A. Colombo Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation Circulation 115 2007 2842 2847
9. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
10. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
11. M.C. Morice, A. Colombo, and B. Meier Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial JAMA 295 2006 895 904
12. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
13. R. Zahn, C.W. Hamm, and S. Schneider Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry) Am J Cardiol 95 2005 1302 1308
14. L. Mauri, T.S. Silbaugh, and R.E. Wolf Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts Circulation 118 2008 1817 1827
15. P.A. Lemos, P.W. Serruys, and R.T. van Domburg Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry Circulation 109 2004 190 195
16. G.W. Stone, A. Rizvi, and W. Newman A large-scale randomized comparison of everolimus-eluting and paclitaxel-eluting stents: one-year clinical outcomes from the SPIRIT IV trial Am J Cardiol 104 2009 XV
17. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
18. I. Bossi, C. Klersy, and A.J. Black In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty J Am Coll Cardiol 35 2000 1569 1576
19. M.S. Chen, J.M. John, D.P. Chew, D.S. Lee, S.G. Ellis, and D.L. Bhatt Bare metal stent restenosis is not a benign clinical entity Am Heart J 151 2006 1260 1264
20. E. Solinas, G. Dangas, and A.J. Kirtane Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention Am J Cardiol 102 2008 311 315
21. C.B. Park, M.K. Hong, and Y.H. Kim Comparison of angiographic patterns of in-stent restenosis between sirolimus- and paclitaxel-eluting stent Int J Cardiol 120 2007 387 390
22. D.H. Steinberg, M.A. Gaglia Jr., and T.L. Pinto Slottow Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents Am J Cardiol 103 2009 491 495
23. S. Rathore, Y. Kinoshita, and M. Terashima A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents EuroIntervention 5 2010 841 846
24. A.R. Assali, A. Moustapha, and S. Sdringola Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial) Am J Cardiol 98 2006 729 733
25. D.H. Steinberg, T.L. Pinto Slottow, and A.N. Buch Impact of in-stent restenosis on death and myocardial infarction Am J Cardiol 100 2007 1109 1113
26. A.K. Nayak, A. Kawamura, and R.W. Nesto Myocardial infarction as a presentation of clinical in-stent restenosis Circ J 70 2006 1026 1029
27. M.S. Lee, A. Pessegueiro, R. Zimmer, D. Jurewitz, and J. Tobis Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era J Invasive Cardiol 20 2008 401 403
28. M.A. Costa, and D.I. Simon Molecular basis of restenosis and drug-eluting stents Circulation 111 2005 2257 2273
29. R.Z. Yusuf, Z. Duan, D.E. Lamendola, R.T. Penson, and M.V. Seiden Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation Curr Cancer Drug Targets 3 2003 1 19
30. S. Huang, and P.J. Houghton Mechanisms of resistance to rapamycins Drug Resist Updat 4 2001 378 391
31. R. Koster, D. Vieluf, and M. Kiehn Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis Lancet 356 2000 1895 1897
32. J.R. Nebeker, R. Virmani, and C.L. Bennett Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project J Am Coll Cardiol 47 2006 175 181
33. G.S. Mintz Features and parameters of drug-eluting stent deployment discoverable by intravascular ultrasound Am J Cardiol 100 2007 26M 35M
34. P. de Jaegere, H. Mudra, and H. Figulla Intravascular ultrasound-guided optimized stent deployment Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries study (MUSIC study) Eur Heart J 19 1998 1214 1223
35. S. Cook, P. Wenaweser, and M. Togni Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation Circulation 115 2007 2426 2434
36. D.H. Steinberg, G.S. Mintz, and L. Mandinov Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies JACC Cardiovasc Interv 3 2010 486 494
37. M.K. Hong, G.S. Mintz, and C.W. Lee Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up Circulation 113 2006 414 419
38. B. Balakrishnan, A.R. Tzafriri, P. Seifert, A. Groothuis, C. Rogers, and E.R. Edelman Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents Circulation 111 2005 2958 2965
39. C.W. Hwang, A.D. Levin, M. Jonas, P.H. Li, and E.R. Edelman Thrombosis modulates arterial drug distribution for drug-eluting stents Circulation 111 2005 1619 1626
40. S. Sonoda, Y. Morino, and J. Ako Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the SIRIUS trial J Am Coll Cardiol 43 2004 1959 1963
41. M.K. Hong, G.S. Mintz, and C.W. Lee Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation Eur Heart J 27 2006 1305 1310
42. K. Fujii, G.S. Mintz, and Y. Kobayashi Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis Circulation 109 2004 1085 1088
43. H. Doi, A. Maehara, and G.S. Mintz Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture Am J Cardiol 103 2009 818 823
44. D.E. Allie, C.J. Hebert, and C.M. Walker Nitinol stent fractures in the SFA: the biomechanical forces exerted on the SFA provide a "stiff" challenge to endovascular stenting Endovasc Today 7 2004 22 34
45. J.J. Popma, K. Tiroch, A. Almonacid, S. Cohen, D.E. Kandzari, and M.B. Leon A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation Am J Cardiol 103 2009 923 929
46. D. Scheinert, S. Scheinert, and J. Sax Prevalence and clinical impact of stent fractures after femoropopliteal stenting J Am Coll Cardiol 45 2005 312 315
47. J. Aoki, G. Nakazawa, and K. Tanabe Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation Catheter Cardiovasc Interv 69 2007 380 386
48. M.S. Lee, D. Jurewitz, J. Aragon, J. Forrester, R.R. Makkar, and S. Kar Stent fracture associated with drug-eluting stents: clinical characteristics and implications Catheter Cardiovasc Interv 69 2007 387 394
49. H. Umeda, T. Gochi, and M. Iwase Frequency, predictors and outcome of stent fracture after sirolimus-eluting stent implantation Int J Cardiol 133 2009 321 326
50. D.J. Kereiakes, H. Wang, and J.J. Popma Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials J Am Coll Cardiol 48 2006 21 31
51. M.A. Costa, D.J. Angiolillo, and M. Tannenbaum Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial) Am J Cardiol 101 2008 1704 1711
52. R. Zahn, C.W. Hamm, and S. Schneider Coronary stenting with the sirolimus-eluting stent in clinical practice: final results from the prospective multicenter German Cypher Stent Registry J Interv Cardiol 23 2010 18 25
53. A. Kastrati, A. Dibra, and J. Mehilli Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents Circulation 113 2006 2293 2300
54. J. Aoki, A. Colombo, and D. Dudek Persistent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study Circulation 112 2005 3876 3883
55. J. Aoki, A.C. Abizaid, and P.W. Serruys Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients J Am Coll Cardiol 46 2005 1670 1676
56. B.E. Claessen, M.A. Beijk, and V. Legrand Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial Circ Cardiovasc Interv 2 2009 339 347
57. Byrne RA. Two-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor drug-eluting stents. Paper presented at: American College of Cardiology/i2 59th Annual Scientific Session; March 1416, 2010; Atlanta, GA.
58. J.J. Popma, M.B. Leon, and J.W. Moses Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries Circulation 110 2004 3773 3780
59. P.A. Lemos, F. Saia, and J.M. Ligthart Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases Circulation 108 2003 257 260
60. I. Iakovou, T. Schmidt, and L. Ge Angiographic patterns of restenosis after paclitaxel-eluting stent implantation J Am Coll Cardiol 45 2005 805 806
61. S.J. Corbett, J. Cosgrave, and G. Melzi Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents Eur Heart J 27 2006 2330 2337
62. A. Colombo, D. Orlic, and G. Stankovic Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation Circulation 107 2003 2178 2180
63. H. Kitahara, Y. Kobayashi, and H. Takebayashi Angiographic patterns of restenosis after sirolimus-eluting stent implantation Circ J 73 2009 508 511
64. J. Cosgrave, G. Melzi, and G.G. Biondi-Zoccai Drug-eluting stent restenosis: the pattern predicts the outcome J Am Coll Cardiol 47 2006 2399 2404
65. S. Garg, K. Smith, and R. Torguson Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent Catheter Cardiovasc Interv 70 2007 9 14
66. Y.H. Kim, B.K. Lee, and D.W. Park Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis Am J Cardiol 98 2006 1451 1454
67. S.S. Lee, M.J. Price, and G.B. Wong Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure Am J Cardiol 98 2006 1345 1348
68. P.A. Lemos, C.A. van Mieghem, and C.A. Arampatzis Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes Circulation 109 2004 2500 2502
69. G.J. Mishkel, A.L. Moore, S. Markwell, M.C. Shelton, and M.E. Shelton Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents J Am Coll Cardiol 49 2007 181 184
70. I.D. Moussa, J.W. Moses, and R.E. Kuntz The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial) Am J Cardiol 97 2006 1582 1584
71. R. Torguson, M. Sabate, and R. Deible Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis Am J Cardiol 98 2006 1340 1344
72. L. Bonello, K. Kaneshige, and A. De Labriolle Vascular brachytherapy for patients with drug-eluting stent restenosis J Interv Cardiol 21 2008 528 534
73. K. Chatani, T. Muramatsu, and R. Tsukahara Predictive factors of re-restenosis after repeated sirolimus-eluting stent implantation for SES restenosis and clinical outcomes after percutaneous coronary intervention for SES restenosis J Interv Cardiol 22 2009 354 361
74. I.M. Singh, S.J. Filby, and F.E. Sakr Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis Catheter Cardiovasc Interv 75 2010 338 342
75. F. Tagliareni, A. La Manna, F. Saia, A. Marzocchi, and C. Tamburino Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories EuroIntervention 5 2010 703 708
76. F. Alfonso, M.J. Perez-Vizcayno, and R. Hernandez A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial J Am Coll Cardiol 47 2006 2152 2160 (Pubitemid 43795079)
77. D.R. Holmes Jr., P. Teirstein, and L. Satler Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial JAMA 295 2006 1264 1273
78. G.W. Stone, S.G. Ellis, and C.D. O'Shaughnessy Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial JAMA 295 2006 1253 1263
79. Chevalier B. The Intra-Drug Eluting Stent (DES) Restenosis Study (CRISTAL). Paper presented at: TCT Conference; September 21, 2010; Washington, DC.
80. J. Mehilli, R.A. Byrne, and K. Tiroch Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study J Am Coll Cardiol 55 2010 2710 2716
81. R. Waksman, A.E. Ajani, and R.L. White Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis Circulation 109 2004 340 344
82. B. Scheller, C. Hehrlein, and W. Bocksch Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter N Engl J Med 355 2006 2113 2124
83. M. Unverdorben, C. Vallbracht, and B. Cremers Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis Circulation 119 2009 2986 2994